Regeneron (REGN) announced that the U.S. Food and Drug Administration has accepted for review the resubmission of the Biologics License ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of EYLEA HD (aflibercept) Injection 8 mg for treating ...

Regeneron, which is seeking FDA approval of linvoseltamab for adults with relapsed/refractory multiple myeloma that has progressed after at least three prior therapies, said the agency set a new ...

It doesn't really mean much that no insider has traded Regeneron Pharmaceuticals shares in the last quarter. While we feel good about high insider ownership of Regeneron Pharmaceuticals ...

Regeneron Pharmaceuticals announced positive ... starts as nonproliferative diabetic retinopathy (NPDR) and often has no warning signs or symptoms. NPDR may progress to proliferative diabetic ...

It doesn't really mean much that no insider has traded Regeneron Pharmaceuticals shares in the last quarter. While we feel good about high insider ownership of Regeneron Pharmaceuticals, we can't say ...

If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Regeneron paid credit card fees ...

Physician-scientist led biotech Regeneron will be responsible for funding preclinical and clinical development and commercialisation activities, while oncology-focused biopharma CytomX will ...

TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals ... of Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July ...

Regeneron said that it was because it had not yet started trials that would be used to confirm accelerated approvals for the two indications. It stressed there were no issues with "clinical ...

Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.